| Literature DB >> 26848197 |
Jose Carlos Tapia1,2,3, Eloy F Ruiz1,3, Oscar J Ponce1,3, German Malaga1,2,3, Jaime Miranda1,2.
Abstract
INTRODUCTION: The inadequate reporting of cross-sectional studies, as in the case of the prevalence of metabolic syndrome, could cause problems in the synthesis of new evidence and lead to errors in the formulation of public policies.Entities:
Keywords: Metabolic syndrome; Peru; adult; epidemiology; prevalence
Mesh:
Year: 2015 PMID: 26848197 PMCID: PMC4732506
Source DB: PubMed Journal: Colomb Med (Cali) ISSN: 0120-8322
Figure 1. Flowchart of the selection of articles
Main features of the articles regarding the prevalence of Metabolic Syndrome of Adults in Peru.
| Reference | Article | Publication Year | Protocol | Publication language | Study Period | City | Population | Sampling Type | Age | Sample Size | MS Criteria |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Soto | A-1 | 2005 | NS | Spanish | 2004 | Lambayeque | Urban, rural | Randomized, multistage, stratified and by clusters | 30 - 70 | 1,000 | NCEP-ATP III12, ILIBLA |
| Guarnizo | A-2 | 2006 | NS | Spanish | 2004 - 2005 | Lambayeque | Urban, rural | Randomized, multistage, stratified and by clusters | 30 - 70 | 621 | NCEP-ATP III12, IDF14, ILIBLA |
| Lorenzo | A-3 | 2006 | PIRS | English | 1999 - 2001 | Lima | Urban | Randomized, multistage, stratified and by clusters | 35 - 64 | 346 | rNCEP-ATP III15, IDF14 |
| Seclén | A-4 | 2006 | PIRS | English | 1999 - 2001 | Lima | Urban | Randomized, multistage, stratified and by clusters | ≥30 | 612 | NCEP-ATP III12 |
| Pajuelo | A-5 | 2007 | ENINBSC | Spanish | 2004 - 2005 | National | Urban, rural | Randomized, multistage, stratified and by clusters | ≥20 | 4,091 | NCEP-ATP III12 |
| Medina-Lezama | A-6 | 2007 | PREVENCION | English | 2004 - 2006 | Arequipa | Urban | Randomized, multistage, stratified and by clusters | 20 - 80 | ,1878 | NCEP-ATP III12, AHA/NHLBI13 |
| Baracco | A-7 | 2007 | NS | English | 2002 - 2003 | Lima, | Urban, rural | Simple randomization | ≥30 | 271 | NCEP-ATP III12 |
| Schargrodsky | A-8 | 2008 | CARMELA | English | 2003 - 2005 | Lima | Urban | Randomized, multistage and stratified | 25 - 64 | 1,652 | NCEP-ATP III12 |
| Cárdenas | A-9 | 2009 | ENINBSC | Spanish | 2004 - 2005 | National | Urban, rural | Randomized, multistage, stratified and by clusters | ≥20 | 4,053 | IDF14 |
| Escobedo | A-10 | 2009 | CARMELA | English | 2003 - 2005 | Lima | Urban | Randomized, multistage and stratified | 25 - 64 | 1,645 | NCEP-ATP III12 |
| Gelaye et al29 | A-11 | 2009 | FRENT Study | English | 2006 | Lima, | Urban | Randomized, multistage and stratified | ≥18 | 1,675 | NCEP-ATP III12 |
| Masterson | A-12 | 2010 | PERU MIGRANT | English | 2007 - 2008 | Lima, | Rural, urban, Urban, rural, rural-urban migrants | Simple randomization | ≥30 | 985 | AHA/NHLBI13 |
| Medina-Lezama | A-13 | 2010 | PREVENCION | English | 2004 - 2006 | Arequipa | Urban | Randomized, multistage, stratified and by clusters | 20 - 80 | 1448 | AHA/NHLBI13, JIS16 |
| Miranda | A-14 | 2011 | PERU MIGRANT | English | 2007 - 2008 | Lima, | Rural, urban Urban, rural, rural-urban migrants | Simple randomization | ≥30 | 989 | JIS16 |
| Boissonet | A-15 | 2011 | CARMELA | English | 2003 - 2005 | Lima | Urban | Randomized, multistage and stratified | 25 - 64 | 1652 | NCEP-ATP III12 |
| Pajuelo | A-16 | 2012 | ENINBSC | Spanish | 2004 - 2005 | <1000, | Urban, rural | Randomized, multistage, stratified and by clusters | ≥20 | 3384 | NCEP-ATP III12 |
| Bernabe-Ortiz | A-17 | 2012 | PERU MIGRANT | English | 2007 - 2008 | Lima | Rural-urban Migrants | Simple randomization | ≥30 | 589 | JIS16 |
MS: Metabolic Syndrome NS: Not stated, NCEP-ATP III: National Cholesterol Education Program-Adult Treatment Panel III; ILIBLA: International Lipid Information Bureau-Latin America; IDF: International Diabetes Federation; rNCEP-ATP III: revised NCEP-ATP III; AHA/NHLBI: American Heart Association/National Heart, Lung and Blood Institute; JIS: Joint Interim Statement
Number of articles that fulfill each recommendation of the STROBE Statement.
| Section | Subsection | Code | Recommendation | Articles that fulfill each STROBE recommendation |
|---|---|---|---|---|
| n(%) | ||||
| Title and abstract | Title and abstract | 1a | Indicate the study's design with a commonly used term in the title or the abstract | 13 (76) |
| 1b | Provide in the abstract an informative and balanced summary of what was found | 15 (88) | ||
| Introduction | Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported. | 17 (100) |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses. | 13 (76) | |
| Methods | Study design | 4 | Present key elements of study design early in the paper. | 17 (100) |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection. | 10 (59) | |
| Participants | 6 | Cross-sectional study: give the eligibility criteria, and the sources and methods of selection of participants. | 17 (100) | |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable. | 16 (94) | |
| Data sources/measurement | 8 | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group. | 16 (94) | |
| Bias | 9 | Describe any efforts to address potential sources of bias. | 7 (41) | |
| Study size | 10 | Explain how the study size was arrived at. | 9 (53) | |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why. | 16 (94) | |
| Statistical methods | 12a | Describe all statistical methods, including those used to control for confounding. | 15 (88) | |
| 12b | Describe any methods used to examine subgroups and interactions. | 15 (88) | ||
| 12c | Explain how missing data was addressed. | 4 (24) | ||
| 12d | Cross-sectional study: If applicable, describe analytical methods taking account of sampling strategy. | 7 (41) | ||
| 12e | Describe any sensitivity analyses. | 1 (6) | ||
| Results | Participants | 13a | Report numbers of individuals at each stage of study-eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 4 (24) |
| 13b | Give reasons for non-participation at each stage. | 5 (299 | ||
| 13c | Consider use of a flow diagram. | 3 (18) | ||
| Descriptive data | 14a | Give characteristics of study participants (eg. Demographic, clinical, social) and information on exposures and potential confounders. | 13 (76) | |
| 14b | Indicate number of participants with missing data for each variable of interest. | 3 (18) | ||
| Outcome data | 15 | Cross-sectional study: report numbers of outcome events or summary measures. | 17 (100) | |
| Main results | 16a | Give unadjusted estimates and , if applicable, confounder-adjusted estimates and their precision (eg. 95% confidence interval). Make clear which confounders were adjusted for and why they were included. | 16 (94) | |
| 16b | Report category boundaries when continuous variables were categorized. | NA | ||
| 16c | If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period. | NA | ||
| Other analyses | 17 | Report other analyses done - eg. analyses of subgroups and interactions, and sensitivity analyses. | 15 (85) | |
| Discussion | Key results | 18 | Summarize key results with reference to study objectives. | 16 (94) |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias. | 9 (53) | |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence. | 14 (82) | |
| Generalisability | 21 | Discuss the generalizability (external validity) of the study results. | 13 (76) | |
| Other information | Funding | 22 | Give the sources of funding and the role of the funders for the present study and, if applicable, for the original study on which present article is based. | 13 (76) |